skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Licartin (Code C104275)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Licartin

Definition: An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.

Label: Licartin

NCI Thesaurus Code: C104275 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1722701  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
(131)I-labeled HAb18 F(ab')(2)
[131I] mAb HAb18G/CD147
Iodine[131I] Metuximab
Iodine I 131 Metuximab

External Source Codes: 
PDQ Closed Trial Search ID 744892
PDQ Open Trial Search ID 744892 (check for NCI PDQ open clinical trial info)
UMLS CUI C1722701

Other Properties:
     Name Value (qualifiers indented underneath)
code C104275
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom